Pinealon — Research, Dosing & Price Guide

Pinealon is a tripeptide bioregulator (Glu-Asp-Arg) developed by the Khavinson laboratory that targets brain tissue, particularly the pineal gland and central nervous system neurons. It is designed to normalize neuronal function, improve sleep quality through melatonin regulation, and provide neuroprotection in aging brain tissue. As a bioregulator, it works through epigenetic modulation of gene expression.

Pinealon penetrates the blood-brain barrier and cell membranes to interact with DNA in neurons and pinealocytes, modulating gene expression related to neurotransmitter synthesis, antioxidant defense, and melatonin production. It normalizes serotonin and melatonin synthesis pathways in the pineal gland, restoring circadian rhythm regulation that deteriorates with age. Additionally, Pinealon upregulates antioxidant enzymes (superoxide dismutase, catalase) in neuronal tissue, reducing oxidative damage that accumulates in the aging brain. It also modulates glutamate signaling, potentially providing neuroprotection against excitotoxicity.

• Khavinson et al. demonstrated Pinealon normalized melatonin production in aged animal pineal gland tissue
• Studies in Bulletin of Experimental Biology and Medicine showed the Glu-Asp-Arg tripeptide regulated gene expression in brain tissue cultures
• Research showed Pinealon improved sleep quality parameters in elderly subjects in observational studies
• Preclinical studies demonstrated neuroprotective effects against oxidative stress-induced neuronal damage
• Khavinson's laboratory showed Pinealon extended lifespan in Drosophila models when administered throughout adulthood

• Oral: 10–20 mg daily in capsule form for 10–30 days
• Repeat cycles every 3–6 months
• Best taken in the evening to align with melatonin production cycles
• For sleep support: 10–20 mg 1–2 hours before bed
• For neuroprotection: 20 mg daily for 20–30 days, cycled every 4–6 months

Known Side Effects

• Drowsiness — expected with evening dosing due to melatonin-stimulating effects; avoid morning dosing if sensitive
• Vivid dreams — reported by some users, consistent with enhanced pineal gland and melatonin activity
• Mild GI discomfort — infrequently reported with oral dosing
• No significant adverse effects reported in published research

Safety Profile

Pinealon has a favorable safety profile consistent with the Khavinson bioregulator family. As a naturally occurring tripeptide, it has inherently low toxicity. No serious adverse events have been reported. Long-term human clinical trial data is limited, with most evidence from Russian observational studies and preclinical research. The peptide is well-tolerated in the cyclic dosing patterns described in the literature. No drug interactions have been identified, though combining with melatonin or other sleep aids may produce additive sedation.

Days 1–5: Improved sleep onset latency (falling asleep faster) and subjective sleep quality are often the first effects noticed. More vivid dreams may occur. Days 5–15: Sleep becomes more restful and restorative. Users report feeling more refreshed upon waking. Daytime cognitive clarity may improve as sleep quality normalizes. Days 15–30: Full effects of neuronal gene expression modulation. Users report sustained improvements in sleep, mood, and cognitive function. Post-cycle: Benefits persist for weeks to months as the epigenetic changes continue to influence neuronal protein synthesis.

Prices sourced from peptides.gg marketplace. Prices may vary.